Paper8940976
A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children.
Marti H and 6 others. Am J Trop Med Hyg, 1996. Cited by 207 papers, by iCite.
Cite this record
ConductScience Library. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Papers, record 8940976. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/8940976
- Disease
- trichuriasis6 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children.
- PubMed
- Publication types
- Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- PubMed
Connected records3
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Albendazole | Major topic |
| Anthelmintics | Major topic |
| Helminthiasis | Major topic |
| Ivermectin | Major topic |
| Strongyloidiasis | Major topic |
| Adolescent | |
| Adult | |
| Ancylostomatoidea | |
| Animals | |
| Ascaris lumbricoides | |
| Child | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Male | |
| Strongyloides stercoralis | |
| Tanzania | |
| Trichuris |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT07045493 | Assessing the Safety and Efficacy of a Combination Therapy for STH in PSAC in Bangladesh | Results |
Source ClinicalTrials.gov
Cited by87
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 207 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42553508 | Duodenal Strongyloidiasis Mimicking Inflammatory Bowel Disease: A Case Report of a 52-Year-Old Immunocompetent Woman. | Clin Med Insights Case Rep | 2026 | https://conductscience.org/library/papers/42553508 | PubMed |
| 42365991 | Investigation of Donor-Transmitted Strongyloides stercoralis Infections in Solid Organ Transplant Recipients, United States, 2012-2024. | Emerg Infect Dis | 2026 | https://conductscience.org/library/papers/42365991 | PubMed |
| 40257544 | Antitumor potential of ivermectin against T-cell lymphoma-bearing hosts. | Med Oncol | 2025 | https://conductscience.org/library/papers/40257544 | PubMed |
| 39719576 | Strongyloidiasis mimics duodenal lymphoma in a patient with systemic lupus erythematosus and antiphospholipid syndrome: a case report. | J Med Case Rep | 2024 | https://conductscience.org/library/papers/39719576 | PubMed |
| 38369483 | Effectiveness of ivermectin mass drug administration in the control of soil-transmitted helminth infections in endemic populations: a systematic review and meta-analysis. | Infect Dis Poverty | 2024 | https://conductscience.org/library/papers/38369483 | PubMed |
| 38357395 | Effectiveness of one and two doses of ivermectin mass drug administration in reducing the prevalence and intensity of soil-transmitted helminth (STH) infections in Western Province, Solomon Islands: a cluster-randomised, before-after analysis. | Lancet Reg Health West Pac | 2024 | https://conductscience.org/library/papers/38357395 | PubMed |
| 37947530 | Who Let the Dogs Out? Unmasking the Neglected: A Semi-Systematic Review on the Enduring Impact of Toxocariasis, a Prevalent Zoonotic Infection. | Int J Environ Res Public Health | 2023 | https://conductscience.org/library/papers/37947530 | PubMed |
| 37068106 | A comparative 'omics' approach for prediction of candidate Strongyloides stercoralis diagnostic coproantigens. | PLoS Negl Trop Dis | 2023 | https://conductscience.org/library/papers/37068106 | PubMed |
| 36540062 | An adaptive phase II/III safety and efficacy randomized controlled trial of single day or three-day fixed-dose albendazole-ivermectin co-formulation versus albendazole for the treatment of Trichuris trichiura and other STH infections. ALIVE trial protocol. | Gates Open Res | 2022 | https://conductscience.org/library/papers/36540062 | PubMed |
| 35848982 | Herbal anthelmintic agents: a narrative review. | J Tradit Chin Med | 2022 | https://conductscience.org/library/papers/35848982 | PubMed |
| 35615701 | Polymicrobial bacteremia and Strongyloides hyperinfection syndrome: Vigilance in patients on corticosteroids. | IDCases | 2022 | https://conductscience.org/library/papers/35615701 | PubMed |
| 35143567 | Impact of ivermectin mass drug administration on burden of soil-transmitted helminths in onchocerciasis control and elimination programs, Yeki district, southwest Ethiopia. | PLoS One | 2022 | https://conductscience.org/library/papers/35143567 | PubMed |
| 34632308 | Efficacy and safety of moxidectin and albendazole compared to ivermectin and albendazole co-administration in adolescents infected with Trichuris trichiura: a randomized controlled trial protocol. | Gates Open Res | 2021 | https://conductscience.org/library/papers/34632308 | PubMed |
| 34576800 | Strongyloidiasis in Children Outside the Tropics: Do We Need to Increase Awareness? | Microorganisms | 2021 | https://conductscience.org/library/papers/34576800 | PubMed |
| 34430453 | Current Use of Ivermectin in Dermatology, Tropical Medicine, and COVID-19: An Update on Pharmacology, Uses, Proven and Varied Proposed Mechanistic Action. | Indian Dermatol Online J | 2021 | https://conductscience.org/library/papers/34430453 | PubMed |
| 34323283 | Broadening the range of use cases for ivermectin - a review of the evidence. | Trans R Soc Trop Med Hyg | 2022 | https://conductscience.org/library/papers/34323283 | PubMed |
| 32669892 | Human strongyloidiasis: identifying knowledge gaps, with emphasis on environmental control. | Res Rep Trop Med | 2014 | https://conductscience.org/library/papers/32669892 | PubMed |
| 32474842 | Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug. | Cancer Chemother Pharmacol | 2020 | https://conductscience.org/library/papers/32474842 | PubMed |
| 32418379 | Effectiveness of Mass Drug Administration on Neglected Tropical Diseases in Schoolchildren in Zanzibar, Tanzania. | Korean J Parasitol | 2020 | https://conductscience.org/library/papers/32418379 | PubMed |
| 32289194 | Anthelmintic drugs for treating ascariasis. | Cochrane Database Syst Rev | 2020 | https://conductscience.org/library/papers/32289194 | PubMed |
Drugs2
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| ALBENDAZOLE | CHEMBL1483 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL1483 | ChEMBL |
| IVERMECTIN | CHEMBL6067487 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL6067487 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/8940976
GET https://conductscience.org/api/papers/v1/8940976/cited_by?page=2